Can't let the post goes unchallenged as there re just too many...

Can't let the post goes unchallenged as there re just too many inaccuracies. First of all , to classify AVR as a biotech stock is just plain wrong. Further to suggest that stocks with merits far outnumber stocks which reach success is only half right, The latter half is right. If you have a science background you would know that not many listed biotech stocks have merits to the scientifically trained. A lot of them just generates investors excitement in a FOMO fashion. In fact the market usually back the wrong horse , just look at a real biotech coy who recently did a placement at 30cts, it has backed to the hilt over the years despite several FDA setbacks. The merits then exists only in the eyes of the beholding investors.
Trading in AVR for years . The stock has lack volatility on 2 fronts , price and volumes. If you manage to do it successfully , you are smarter than Elon Musk then or maybe there is a lot of gas bagging.
If you still believe the science underpinning AVR is risky, then you are clearly at odds with several very very eminent cardiologist and cardiac surgeons. The greatest risk here is Wayne's failure or refusal to look after the share price.